RELMADA THERAPEUTICS, INC. Unrealized Gain (Loss) on Investments
RELMADA THERAPEUTICS, INC. (RLMD) reported Unrealized Gain (Loss) on Investments of -$167.26 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. unrealized gain (loss) on investments for the quarter ending 2026-06-30 was -$167.26K.
- RELMADA THERAPEUTICS, INC. unrealized gain (loss) on investments for the quarter ending 2026-03-31 was -$540.10K, a 446.81% decline year-over-year.
- RELMADA THERAPEUTICS, INC. unrealized gain (loss) on investments for the quarter ending 2025-12-31 was $186.04K.
- RELMADA THERAPEUTICS, INC. unrealized gain (loss) on investments for the quarter ending 2025-09-30 was $70.28K, a 74.77% decline year-over-year.
- RELMADA THERAPEUTICS, INC. unrealized gain (loss) on investments for fiscal 2025 was $398.25K, a 5813.21% increase from fiscal 2024.
- RELMADA THERAPEUTICS, INC. unrealized gain (loss) on investments for fiscal 2024 was $6.74K, a 99.82% decline from fiscal 2023.
- RELMADA THERAPEUTICS, INC. unrealized gain (loss) on investments for fiscal 2023 was $3.82M.
- RELMADA THERAPEUTICS, INC. unrealized gain (loss) on investments for fiscal 2022 was -$4.22M.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$167.26K 10-Q · filed 2026-08-06 | -$707.35K 10-Q · filed 2026-08-06 | -$521.31K derived: sum of 3 quarters · filed 2026-08-06 | -$451.04K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$540.10K 10-Q · filed 2026-05-12 | -$354.05K derived: sum of 2 quarters · filed 2026-05-12 | -$283.78K derived: sum of 3 quarters · filed 2026-05-12 | -$297.57K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $186.04K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $256.32K derived: sum of 2 quarters · filed 2026-03-19 | $242.52K derived: sum of 3 quarters · filed 2026-08-06 | $398.25K 10-K · filed 2026-03-19 |
| 2025-09-30 | $70.28K 10-Q · filed 2025-11-13 | $56.48K derived: sum of 2 quarters · filed 2026-08-06 | $212.21K 10-Q · filed 2025-11-13 | -$64.86K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$13.80K 10-Q · filed 2026-08-06 | $141.93K 10-Q · filed 2026-08-06 | -$135.13K derived: sum of 3 quarters · filed 2026-08-06 | $143.42K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $155.73K 10-Q · filed 2026-05-12 | -$121.34K derived: sum of 2 quarters · filed 2026-05-12 | $157.22K derived: sum of 3 quarters · filed 2026-05-12 | $111.75K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$277.07K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.49K derived: sum of 2 quarters · filed 2026-03-19 | -$43.98K derived: sum of 3 quarters · filed 2026-03-19 | $6.74K 10-K · filed 2026-03-19 |
| 2024-09-30 | $278.56K 10-Q · filed 2025-11-13 | $233.09K derived: sum of 2 quarters · filed 2025-11-13 | $283.80K 10-Q · filed 2025-11-13 | $4.03M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$45.47K 10-Q · filed 2025-08-07 | $5.25K 10-Q · filed 2025-08-07 | $3.76M derived: sum of 3 quarters · filed 2025-08-07 | $3.18M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $50.71K 10-Q · filed 2025-05-12 | $3.80M derived: sum of 2 quarters · filed 2025-05-12 | $3.22M derived: sum of 3 quarters · filed 2025-05-12 | $2.58M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $3.17M derived: sum of 2 quarters · filed 2025-03-27 | $2.53M derived: sum of 3 quarters · filed 2025-03-27 | $3.82M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$579.15K 10-Q · filed 2024-11-07 | -$1.22M derived: sum of 2 quarters · filed 2024-11-07 | $72.33K 10-Q · filed 2024-11-07 | -$250.79K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$639.63K 10-Q · filed 2024-08-07 | $651.48K 10-Q · filed 2024-08-07 | $328.36K derived: sum of 3 quarters · filed 2024-08-07 | -$619.16K derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $1.29M 10-Q · filed 2024-05-08 | $967.99K derived: sum of 2 quarters · filed 2024-05-08 | $20.48K derived: sum of 3 quarters · filed 2024-05-08 | -$1.17M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$323.12K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$1.27M derived: sum of 2 quarters · filed 2024-03-19 | -$2.46M derived: sum of 3 quarters · filed 2024-03-19 | -$4.22M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$947.51K 10-Q · filed 2023-11-08 | -$2.13M derived: sum of 2 quarters · filed 2023-11-08 | -$3.90M 10-Q · filed 2023-11-08 | -$4.13M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$1.19M 10-Q · filed 2023-08-08 | -$2.95M 10-Q · filed 2023-08-08 | -$3.18M derived: sum of 3 quarters · filed 2023-08-08 | -$3.09M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$1.76M 10-Q · filed 2022-05-05 | -$1.99M derived: sum of 2 quarters · filed 2023-03-23 | -$1.91M derived: sum of 3 quarters · filed 2023-03-23 | -$2.20M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-12-31 | -$231.68K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$144.94K derived: sum of 2 quarters · filed 2023-03-23 | -$434.22K derived: sum of 3 quarters · filed 2023-03-23 | -$611.38K 10-K · filed 2023-03-23 |
| 2021-09-30 | $86.75K 10-Q · filed 2022-11-10 | -$202.54K derived: sum of 2 quarters · filed 2022-11-10 | -$379.70K 10-Q · filed 2022-11-10 | -$531.40K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$289.28K 10-Q · filed 2022-08-11 | -$466.44K 10-Q · filed 2022-08-11 | -$618.15K derived: sum of 3 quarters · filed 2022-08-11 | -$614.20K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$177.16K 10-Q · filed 2022-05-05 | -$328.87K derived: sum of 2 quarters · filed 2022-05-05 | -$324.92K derived: sum of 3 quarters · filed 2022-05-05 | $897.02K derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | -$151.71K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | -$147.76K derived: sum of 2 quarters · filed 2022-03-25 | $1.07M derived: sum of 3 quarters · filed 2022-03-25 | $139.27K 10-K · filed 2022-03-25 |
| 2020-09-30 | $3.95K 10-Q · filed 2021-11-12 | $1.23M derived: sum of 2 quarters · filed 2021-11-12 | $290.97K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $1.22M 10-Q · filed 2021-08-10 | $287.03K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$934.92K 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |